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exportation of pharmaceutical products by target countries has also been gathered 
through library and the Internet researches. RESULTS: The result of study regarding 
rate of export showed an increasing rate (each year growth) of 20%, (from 1348 to 
2881 million $), 18% (from 1978 to 3777 million $), 10% (from 193 to 295 million 
$) for India, China and Jordan respectively as developing countries during 2001–2005 
and 44% (from 2435, 6722 million $), 40% (from 1450 to 3483 million $) for Spain 
and Canada in the same period of time as developed countries. Iran’s pharmaceutical 
export reached to 66.4 from 13 million $ in the same period. CONCLUSIONS: While 
Iran has not experienced a successful exporting situation at the same period of time 
India, Jordan, Spain and Canada have taken successful steps in the ﬁeld of exportation 
during recent years by implementing desirable exports expanding policies; it seems 
that disharmonies and lack of a desirable policy and insufﬁciencies of applied proce-
dures are responsible for mentioned situation of Iran.
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OBJECTIVES: The appropriate and accurate classiﬁcation of outpatient infusion ser-
vices is a strategic hospital responsibility having widespread operational impact. Site 
of care designation, speciﬁcally whether a service setting is provider-based or non-
provider-based, determines the mechanism of Medicare payment and dictates the 
program structure required for operational compliance. This project was designed 
to review models of hospital outpatient drug administration services; discuss the 
Medicare reimbursement implications, and illustrate options for hospital planning. 
METHODS: The history and evolution of provider-based criteria was arrayed along 
a timeline and the relevant regulations and legislation cited. The provider-based deﬁni-
tions and criteria were described and the concept of “incident-to the physician’s ser-
vices” was explored as a Medicare requirement. Provider and non-provider models 
were compared and contrasted for the following characteristics: functional appearance 
and processes; Medicare billing and payment, and patient ﬁnancial responsibilities. 
Hospital strategic choices were reviewed. RESULTS: There are two primary model 
options for hospital outpatient infusion service delivery: provider-based and non-
 provider-based. The provider-based model allows infusion services to operate as a 
hospital department and to bill and receive payment from Medicare under the outpa-
tient prospective payment system, as long as the regulatory deﬁnitions and criteria 
are met. Non-provider-based infusion services operate as a medical practice model, 
allowing the hospital to bill and receive payment from Medicare under the physician 
fee schedule. CONCLUSIONS: Hospitals choosing to offer infusion services may do 
so via either model. Each has unique implications for Medicare reimbursement, 
hospital operations and beneﬁciary ﬁnancial responsibility. With informed know- 
ledge of the options, hospital decision-makers are better prepared to position infusion 
programs appropriately within the context of their facility’s mission and 
capabilities.
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OBJECTIVES: In the Netherlands, orphan drug developers can be exempted from 
providing a full pharmacoeconomic evaluation when applying for reimbursement,      
whereas in Scotland no such exceptions can be made. METHODS: All orphan drug 
reimbursement reports from the Dutch reimbursement institution (CFH) and guidance 
issued by the Scottish Medicines Consortium (SMC) were collected.    RESULTS: 38 
orphan drugs were submitted to the CFH; 37 to the SMC. Only one CFH submission 
included a full pharmacoeconomic evaluation, while almost all SMC submissions did. 
The CFH gave positive recommendations for reimbursement for 36 submissions    
(95%). In contrast, of the 37 SMC submissions, 19 (51%) received a positive recom-
mendation for use. Half of the SMC submissions reported an unfavourable cost-
 effectiveness outcome; almost all of these received a negative recommendation. 
CONCLUSIONS: Differences in policies and requirements for submissions for orphan 
drugs can explain discrepancies in reimbursement and guidance for use decisions 
between Scotland and the Netherlands.
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OBJECTIVES: Since 2005 it is obligatory in the Netherlands to submit pharmaco-
economic evidence for innovative drugs. The aim of our study is to describe the role 
of pharmacoeconomics in decision-making in the Dutch reimbursement system. 
METHODS: We used the analytical Hutton framework for assessing ‘fourth-hurdle’ 
systems to analyse the Dutch drug reimbursement system. We examined policy docu-        
ments, explored literature and conducted interviews with policy makers and represen-
tatives of the pharmaceutical industry. RESULTS: Different schemes exist for inpatient 
and outpatient drugs. Expensive hospital drugs obtain positive decisions without 
extensive pharmacoeconomic evidence. After a period of three years, it is required to 
submit evidence on real-world cost-effectiveness. However, the ﬁrst reassessments are      
yet to be conducted. In contrast, innovative outpatient drugs are only reimbursed after 
an assessment of pharmacoeconomic evidence. The Dutch Health Care Insurance 
Board and the Pharmaceutical Advisory Committee advise the minister on the robust-
ness of cost-effectiveness evidence, whereas the latter takes the ﬁnal decision. Recently, 
assessment and appraisal have become two separate phases in decision-making. The 
impact of the appraisal committee is still unclear. The near future will show if they 
take the lead on advising on value for money. No party has taken up this role until 
now, only the Council for Public Health and Healthcare suggested a threshold range. 
The industry, however, anticipates that the new committee just adds another hurdle. 
CONCLUSIONS: The importance of pharmacoeconomics has increased in Dutch 
drug reimbursement decision-making, but plays an uncertain role. It seems that the 
‘fourth-hurdle’ system is more lenient towards expensive inpatient and orphan drugs. 
In future research we focus on investigating reimbursement dossiers to reveal implicit        
and explicit decision criteria. Furthermore, we aim to research reimbursement systems 
within several European countries to obtain insight into best practice systems that 
deliver value for money.
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OBJECTIVES: The mature health economies as exampled by the G7 Countries have 
developed collectively a plethora of supply and demand side controls to control access 
to medicines. Health Policy makers, Payers and Health insurance bodies are expected 
to utilize new P & R tools to ensure value for money. A survey was undertaken 
amongst health policy experts to understand trends in P & R Policy reform. 
METHODS: Over 2008/9 23 health policy experts were interviewed from 7 health 
economies. Speciﬁc examples of new and emerging policy reforms were sought with 
insights requested into how the market access landscape is likely to be transformed 
over the next decade. P & R tools were classiﬁed using the well recognized nomen-
clature of supply and demand side controls. RESULTS: There is harmonization of 
thinking amongst health policy leads that unregulated access to medicines is not a 
tenable or sustainable option. The EU has a long established group of P & R policy 
tools to choose from. New initiatives such as ﬂexible pricing and innovative patient 
access schemes are becoming more prevalent. In the US an absence of supply side-side 
initiatives at a Government level leave individual States to negotiate on Medicare 
programmes. New policy initiatives emerging include a focus on cost-effectiveness and 
health economics to prioritise drug spend. CONCLUSIONS: The EU markets have to 
date led the way in developing innovative P & R tools, but even within these markets, 
tools have had various degree of success in terms of overall cost containment. 
However, the US demonstrated to be the most dynamic health care system likely to 
undergo policy reforms in the near future led by the American Rescue and Recovery 
Act (ARRA). Although there are clear differences, the recently announced changes 
may result in a closer resemblance between the US and EU P & R markets.
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OBJECTIVES: A fundamental assumption of Medicare’s rate setting methodology for 
Speciﬁed Covered Outpatient Drugs (SCODs) is that pharmacy overhead and handling 
costs are included by hospitals in their drug charges. Provider reported data does not 
consistently support that assumption. This study explores the history and current 
status of this debate and presents additional evidence of the continued variability in 
hospital drug charge composition and reporting. METHODS: Preparation input 
included review of legislation and Medicare regulations relevant to outpatient drug 
payment and pharmacy overhead. Historic discussions of pharmacy costs and charges 
were identiﬁed and accumulated in an indexed database. Data regarding the nature 
of hospital drug charges were collected from a 2008 hospital survey (n  356). 
RESULTS: Historic analyses of Medicare’s rate setting methodology for SCODs 
support the hypothesis that hospitals may be underpaid for these products, due in part 
to underestimation of the related costs for pharmacy handling and services. Medicare’s 
methodology relies upon hospital reported charges submitted on the cost report. The 
hospital survey revealed that 40% of the respondents do not include in their drug 
charges amounts for anything beyond drug acquisition cost. CONCLUSIONS: Medi-
care’s outpatient drug payment rates continue to be derived from hospital charges 
which have demonstrated wide variability in recognizing pharmacy overhead costs. 
Although there have been recurring recommendations to Medicare for rate setting 
methodologies that can adequately address drug handling as well as acquisition costs, 
outpatient hospital drug reimbursement has now declined for two consecutive years. 
Failure to resolve this issue may threaten the ability of hospital providers to continue 
to offer outpatient drug services.
